Oryzon Genomics S.A (ORY) | Stock Overview & Key Data
Oryzon Genomics S.A. | Mid-cap | Healthcare
Oryzon Genomics S.A. | Mid-cap | Healthcare
Oryzon Genomics S.A Performance Comparison
Stock Range
Today's Range
Low: €2.82
High: €3.15
on September 18, 2025
52 Week Range
Low: €1.40
High: €3.69
on January 27, 2025
on February 24, 2025
All-Time High: €5.25 on December 14, 2015
Explore how other Spanish stocks compare to their 52-week ranges: View ES Market 52-Week Insights
Key Statistics
Market Cap
€217.8M
EPS
-0.06
P/E Ratio (TTM)
-47.70
Forward P/E
-16.24
P/B Ratio
1.87
PEG Ratio
-16.24
Div. Yield
N/A
ROE
-4.20%
Beta
0.427
Debt to Equity
15.87
Financial Highlights
Profitability
Gross Margin
N/A
Operating Margin
6.30%
Profit Margin
-56.48%
Returns and Earnings
Return on Assets (TTM)
-2.52%
Return on Equity (TTM)
-4.20%
EBITDA
€-4.9M
Net Income (TTM)
€-4.2M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
€0.12
Quarterly Revenue Growth (YoY)
2.70%
Quarterly Earnings Growth (YoY)
N/A
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Oryzon Genomics S.A ORY | 217.81M Mid-cap | 13.24% | 15.79% | 8.45% | -12.75% | 105.33% | 67.39% | 43.26% | 6.21% |
| Pharma Mar S.A PHM | 1.59B Large-cap | 1.10% | 3.25% | 7.71% | -2.73% | 9.12% | 83.43% | 60.22% | -14.70% |
| Atrys Health S.A ATRY | 212.52M Mid-cap | -2.47% | -6.12% | 0.36% | -13.21% | -21.14% | -10.68% | -52.90% | -62.19% |
| Vytrus Biotech S.A VYT | 44.02M Small-cap | 0.00% | 1.82% | 39.30% | 100.00% | 159.26% | 74.45% | 80.65% | 98.58% |
| Biotechnology Assets BST | 26.33M Small-cap | -2.56% | 5.56% | 22.58% | 15.15% | 35.71% | 22.58% | 322.22% | -37.70% |
| Grifols, S.A GRF | 7.38B Large-cap | -2.70% | -5.33% | 14.64% | 23.57% | 25.79% | 21.06% | 18.76% | -51.01% |
Ownership & Short Interest
Insider Ownership
20.91%
Institutional Ownership
3.57%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
223K
Average 90-Day Volume
324K
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is ORY's 52-week high and low?
- In the last 52 weeks, Oryzon Genomics S.A reached a high of €3.69 (on February 24, 2025) and a low of €1.40 (on January 27, 2025).
- What is the market cap and P/E ratio for ORY?
- Curious about Oryzon Genomics S.A's size and valuation? Its market capitalization stands at 217.81M. When it comes to valuation, the P/E ratio (trailing twelve months) is -47.70, and the forward P/E (looking ahead) is -16.24.
- Does ORY pay dividends? If so, what's the yield?
- As for dividends, Oryzon Genomics S.A isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Oryzon Genomics S.A's main competitors or similar companies to consider before investing?
When looking at Oryzon Genomics S.A, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Pharma Mar S.A
PHM1.59B Healthcare Biotechnology 83.43% 60.22% Atrys Health S.A
ATRY212.52M Healthcare Biotechnology -10.68% -52.90% Vytrus Biotech S.A
VYT44.02M Healthcare Biotechnology 74.45% 80.65% Biotechnology Assets
BST26.33M Healthcare Biotechnology 22.58% 322.22% Grifols, S.A
GRF7.38B Healthcare Drug Manufacturers - General 21.06% 18.76% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Oryzon Genomics S.A.? (e.g., ROE, Debt/Equity)
- To get a sense of Oryzon Genomics S.A's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -4.20%, the Debt to Equity ratio from the most recent quarter is 15.87, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for ORY?
- Looking at Oryzon Genomics S.A's growth, its revenue over the trailing twelve months (TTM) was €7M. Compared to the same quarter last year (YoY), quarterly revenue grew by 2.70%, and quarterly earnings saw a YoY growth of N/A.
- How much of ORY stock is held by insiders and institutions?
- Wondering who owns Oryzon Genomics S.A stock? Company insiders (like executives and directors) hold about 20.91% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 3.57%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.